Provided are inflammatory cytokine production inhibitors which inhibit the production of the inflammatory cytokines TNF-α and IL-1β and can be applied to drugs effective against inflammatory diseases caused by overproduction of these inflammatory cytokines, such as chronic inflammation (e.g., rheumatoid arthritis, ulcerative colitis) and Crohn's disease, as well as type 2 diabetes, depression, obesity, sepsis, atherosclerosis, dermatitis, dementia, schizophrenia, and Parkinson's disease, and also to foods and drinks such as health foods. The inflammatory cytokine production inhibitors contain as an active ingredient an enzyme-treated whey obtained by contacting whey with β-galactosidase. The enzyme-treated whey is obtained by further contacting with sialidase.
The present invention aims to provide a senescence inhibitor formed from a material of biological origin. The present invention relates to a senescence inhibitor containing vitamin D-binding protein.
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12N 9/38 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons bêta-galactose-glycoside, p. ex. bêta-galactosidase
C12P 21/06 - Préparation de peptides ou de protéines préparés par hydrolyse d'une liaison peptidique, p. ex. hydrolysats
Inflammatory cytokine production inhibitors containing a tomato extract as an active ingredient, which inhibit the production of the inflammatory cytokines TNF-α and IL-6 and can be applied to drugs effective against inflammatory diseases caused by overproduction of these inflammatory cytokines, such as rheumatoid arthritis, ulcerative colitis, Crohn's disease, and type 2 diabetes, as well as to foods and drinks such as health foods, wherein the tomato extract is a raw tomato extract that is a high-molecular-weight fraction having a molecular weight of 10,000 or higher obtained by molecular weight fractionation.
A macrophage activator containing a Gc protein is provided by a simple process. The macrophage activator contains a Gc protein with no N-acetylgalactosamine attached thereto.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
The purpose of the present invention is to provide a senescence inhibitor that utilizes a material of biological origin. The present invention is directed to a senescence inhibitor containing a vitamin D binding protein.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present invention provides a macrophage activator comprising Gc protein by a simple process. This macrophage activator comprises Gc protein to which no N-acetylgalactosamine is attached.
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
Provided are inflammatory cytokine production inhibitors which inhibit the production of the inflammatory cytokines TNF-α and IL-1β and can be applied to drugs effective against inflammatory diseases caused by overproduction of these inflammatory cytokines, such as chronic inflammation (e.g., rheumatoid arthritis, ulcerative colitis) and Crohn's disease, as well as type 2 diabetes, depression, obesity, sepsis, atherosclerosis, dermatitis, dementia, schizophrenia, and Parkinson's disease, and also to foods and drinks such as health foods. The inflammatory cytokine production inhibitors contain as an active ingredient an enzyme-treated whey obtained by contacting whey with β-galactosidase. The enzyme-treated whey is obtained by further contacting with sialidase.
To provide an inflammatory cytokine production inhibitor that inhibits the production of inflammatory cytokines such as TNF-α and IL-1β and is therefore applicable to drugs and foods and beverages such as health foods which are efficacious against inflammatory diseases caused by the excessive production of these inflammatory cytokines. Examples of the inflammatory diseases include chronic inflammations such as rheumatoid arthritis and ulcerative colitis, Crohn disease and, moreover, type 2 diabetes, depression, obesity, sepsis, atherosclerotic cardiovascular disease, dermatitis, major neurocognitive disorder, integration dysfunction syndrome and Parkinson disease. An inflammatory cytokine production inhibitor characterized by comprising, as an active ingredient, enzymatically treated whey prepared by contacting milk whey with β-galactosidase, wherein the enzymatically treated whey is obtained by further contacting with sialidase.
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
This inflammatory cytokine production inhibitor inhibits the production of TNF-α and IL-6 inflammatory cytokines, uses a tomato extract as an active ingredient, can be applied to food and beverages such as health food products and the like, and can be applied as a drug that is effective against inflammatory diseases, such as rheumatoid arthritis, ulcerative colitis, Crohn's disease, and type 2 diabetes, which are caused by the excessive production of said inflammatory cytokines. The inflammatory cytokine production inhibitor is a raw tomato extract in which the molecular weight of a high polymer fraction is at least 10,000 by molecular weight fractionation.
A61K 36/81 - Solanaceae (famille de la pomme de terre), p. ex. tabac, Solanum ptycanthum, tomate, belladone, poivron ou datura
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
10.
Enzyme-treated milk product, preparation method thereof, composition, and products
An object of the present invention is to provide an enzyme-treated milk product, a method for preparing the same, a composition thereof comprising a pharmaceutical composition, and a product thereof comprising a pharmaceuticals. The enzyme-treated milk product can be obtained by a method for producing an enzyme-treated milk product including a step for bringing milk into contact with β-galactosidase.
A23L 29/275 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des agents gélifiants ou épaississants d'origine animale, p. ex. chitine
Provided are an enzyme-treated milk product, a method for producing the same, a composition thereof comprising a pharmaceutical composition, and a product thereof comprising a pharmaceutical. An enzyme-treated milk product obtained by a method for producing an enzyme-treated milk product including a step for bringing milk into contact with β-galactosidase.
A23C 9/12 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes
A23C 21/00 - Petit-laitPréparations à base de petit-lait
A23L 2/00 - Boissons non alcooliséesCompositions sèches ou concentrés pour les fabriquer Leur préparation ou leur traitement
A23L 29/275 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des agents gélifiants ou épaississants d'origine animale, p. ex. chitine
An object of the present invention is to provide a method of preparing an enzyme-treated bovine colostrum, comprising a step of bringing a bovine colostrum into contact with β-galactosidase, and a pharmaceutical composition comprising the enzyme-treated bovine colostrum. The enzyme-treated bovine colostrum is useful for treatment, prevention, amelioration and maintenance of remission of diseases such as a cancer and an infectious disease.
Provided are: a bovine colostrum enzyme processed product production method including a step in which bovine colostrum is caused to come in contact with β-galactosidase; and a pharmaceutical composition, etc., including said bovine colostrum processed product. The bovine enzyme processed product is useful for the treatment, prevention, improvement and remission maintenance of conditions such as cancer and infectious diseases, etc.
brevets
